Txcell granted US orphan drug designation for Col-Treg
Monday, September 14, 2015
Txcell granted US orphan drug designation for Col-Treg in the treatment of chronic non-infectious uveitis.
Txcell plans to move Col-Treg into a first clinical study in 2016, with top line results expected end 2017.
reuters.com
